Infliximab is recommended as a possible treatment for adults with plaque psoriasis only if:
- their condition is very severe and
- their condition has not improved with other treatments such as ciclosporin, methotrexate or PUVA (psoralen and long-wave ultraviolet radiation), or they have had side effects with these inthe past or there is a medical reason why they should not be given these treatments.
Infliximab treatment should be continued beyond 10 weeks only if the psoriasis has clearly improved within this time.
The severity of a person's psoriasis before and during treatment should be assessed by considering the redness, thickness and scaliness of the plaques, the area of the body involved, and how the condition affects the person's quality of life.
When assessing a person's psoriasis, healthcare professionals should take into account any disabilities or difficulties in communicating, which might mean that the standard assessments do not provide accurate information about their condition.